rs15869 at miRNA binding site in BRCA2 is associated with breast cancer susceptibility
- 422 Downloads
BRCA1 and BRCA2 mutations confer an increased lifetime risk of breast cancer; however, the associations of microRNA (miRNA) binding site single nucleotide polymorphisms (SNPs) in 3′ untranslated region (3′-UTR) of BRCA1 and BRCA2 with breast cancer (BC) risk were rarely reported. In this case–control study (498 BC patients and 498 matched controls), three SNPs (rs8176318, rs12516 and rs15869) were selected in the 3′-UTR of BRCA1 and BRCA2 genes, which were within miRNA-binding seed regions and might have potential function to regulate the expression of BRCA1/BRCA2. Unconditional logistic regression model was used to analyze the association between three SNPs and BC risk with adjustment of reproductive factors, and Student’s t test was performed to assess relative expression of BRCA2 in human breast cancer cell lines. Multifactor dimensionality reduction method was applied to calculate gene–reproductive factors interactions. A novel finding showed that AC [odds ratio (OR) 1.524; 95% confidence interval (CI) 1.141–2.035] genotype of rs15869 in BRCA2 could increase the risk of BC and recombinant plasmid-pGenesil-1-miR-627 could negatively regulate the expression of BRCA2 in MCF-7 and MDA-MB-231 cells. Gene–reproductive factors interactions analysis revealed that rs15869 together with age at menarche and number of pregnancy could increase the risk of BC by 2.39-fold and TT genotype (OR 0.316; 95% CI 0.130–0.767) of rs8176318 had a significant association with progesterone receptor status in BC patients. Our findings suggest that the miRNA-binding SNPs in BRCA1/BRCA2 and their interaction with reproductive factors might contribute to BC risk, and miR-627 might down-regulate BRCA2 expression in MCF-7 and MDA-MB-231 cells.
KeywordsBreast cancer miRNA binding site Genetic susceptibility Interaction BRCA miRNA-627
This work was financially supported by the National Natural Science Foundation of China (81202278) and Medical Science and Technology Key Projects of Henan Province (201303005 and 20150374).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Signed informed consent was obtained from each participant. The study was approved by the Ethical Review Committee of Zhengzhou University Committee for Medical and Health Research Ethics.
- 9.Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–11. doi: 10.1200/JCO.2014.57.1414.CrossRefPubMedGoogle Scholar
- 13.Brewster BL, Rossiello F, French JD, Edwards SL, Wong M, Wronski A, et al. Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site. Hum Mutat. 2012;33(12):1665–75. doi: 10.1002/humu.22159.CrossRefPubMedGoogle Scholar
- 17.Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, et al. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat Res. 2011;717(1–2):109–15. doi: 10.1016/j.mrfmmm.2010.10.002.CrossRefPubMedGoogle Scholar
- 19.Becher H, Schmidt S, Chang-Claude J. Reproductive factors and familial predisposition for breast cancer by age 50 years. A case–control-family study for assessing main effects and possible gene-environment interaction. Int J Epidemiol. 2003;32(1):38–48. doi: 10.1093/ije/dyg003.CrossRefPubMedGoogle Scholar
- 20.Andrieu N, Prevost T, Rohan T, Luporsi E, Le MG, Gerber M, et al. Variation in the interaction between familial and reproductive factors on the risk of breast cancer according to age, menopausal status, and degree of familiality. Int J Epidemiol. 2000;29(2):214–23. doi: 10.1093/ije/29.2.214.CrossRefPubMedGoogle Scholar
- 28.Salim H, Akbar NS, Zong D, Vaculova AH, Lewensohn R, Moshfegh A, et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer. 2012;107(8):1361–73. doi: 10.1038/bjc.2012.382.CrossRefPubMedPubMedCentralGoogle Scholar
- 35.Figueiredo JC, Brooks JD, Conti DV, Poynter JN, Teraoka SN, Malone KE, et al. Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status. Breast Cancer Res Treat. 2011;127(3):819–29. doi: 10.1007/s10549-010-1285-1.CrossRefPubMedGoogle Scholar
- 36.Erturk E, Cecener G, Polatkan V, Gokgoz S, Egeli U, Tunca B, et al. Evaluation of genetic variations in miRNA-binding sites of BRCA1 and BRCA2 genes as risk factors for the development of early-onset and/or familial breast cancer. Asian Pac J Cancer Prev. 2014;15(19):8319–24. doi: 10.7314/apjcp.2014.15.19.8319.CrossRefPubMedGoogle Scholar
- 41.Milne RL, Gaudet MM, Spurdle AB, Fasching PA, Couch FJ, Benitez J, et al. Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case–control study. Breast Cancer Res BCR. 2010;12(6):R110. doi: 10.1186/bcr2797.CrossRefPubMedGoogle Scholar
- 42.Campa D, Kaaks R, Le Marchand L, Haiman CA, Travis RC, Berg CD, et al. Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst. 2011;103(16):1252–63. doi: 10.1093/jnci/djr265.CrossRefPubMedPubMedCentralGoogle Scholar